McBee, Moore & Vanik IP, LLC began in 2016 when partners Susan McBee, C.G. Moore, David Vanik and 12 employees came together to form a new patent law firm with improved client service as the ultimate goal. This year, the firm is celebrating six years together.
5 Questions With Tim Harvey, Co-Founder and CEO of Owl Peak Labs “5 Questions With…” is a weekly BioBuzz series where we reach out to interesting people to share a little about themselves, their work, and maybe something completely unrelated. This week we welcome Tim Harvey, Co-Founder and CEO at Owl Peak Labs. Owl Peak [….]
SK Inc., the Second Largest Conglomerate in South Korea, has invested $350 million in the Center for Breakthrough Medicines
The Center for Breakthrough Medicines (CBM) announced today that it has received $350 million in equity financing from SK Inc. (KRX: 034730) (SK). CBM is partnering with SK to create the world’s largest end-to-end cell and gene therapy contract development and manufacturing organization (CDMO).
Castle Creek Biosciences Acquires Novavita Thera to Expand Innovative Cell and Gene Therapy Platform
Castle Creek Biosciences, Inc., a late-clinical stage cell and gene therapy company focused on developing and preparing to commercialize disease-modifying and potentially curative therapies for rare genetic diseases, today announced it has acquired Novavita Thera, Inc., a preclinical gene therapy company focused on rare liver and metabolic diseases. The acquisition expands Castle Creek’s technology platform by adding in vivo capabilities to its existing ex vivo approach, and broadens Castle Creek’s development pipeline beyond skin and connective tissue disorders to rare liver diseases.
TEDCO’s Maryland Venture Fund Invests $500K in Maryland Technology Start-up Transformania is a Software as a Service (SaaS) with a data quality solution for Customer Relationship Management (CRM) software COLUMBIA, Md. (January 12, 2022)—TEDCO, Maryland’s economic engine for technology companies, announced today its Maryland Venture Fund (MVF) invested $500K in Transformania. TEDCO’s MVF is an early-stage, venture capital [….]
Erica Kimmel and Nina Manguiri Join Gilbane Building Company to Expand Business Development in Maryland
Gilbane Building Company is pleased to announce the addition of Erica Kimmel and Nina Manguiri as Business Development Managers in the Baltimore, MD office. Together they bring over 39 years of strategic sales experience. Working alongside Greg Permison, who joined Gilbane in 2018, they will support Gilbane’s business development effort for continued growth and expansion in the Maryland market.
As years went by, I started to realize that there was a whole world of opportunities for PhDs beyond the bench – careers that were just as intellectually stimulating and still scratched that scientific itch without ever having to pick up a pipette. However, the road to reach these careers was a bit foggier compared to academia. Did I need to do a postdoc? How important are publications? How do I make myself stand out?
Ezekiel Kelley Joins Workforce Genetics as Director of Operations and Workforce Development Solutions
Workforce Genetics welcomes Ezekiel Kelley as the new Director of Operations and Workforce Development Solutions. Ezekiel will establish and implement efficient operating systems to drive growth across the whole organization – including the Recruiting and BioBuzz divisions. Additionally, he will be the head architect for building innovative new workforce solutions; including a new online community and talent marketplace that seeks to expand access to virtual workforce development and education tools, increase career mobility, and democratize access to rewarding life science careers.
Novavax and Serum Institute of India File for Emergency Use Authorization of Novavax’ COVID-19 Vaccine in South Africa
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, and Serum Institute of India Pvt. Ltd. (SII), the world’s largest vaccine manufacturer by volume, today announced a regulatory submission to the South African Health Products Regulatory Agency (SAHPRA) for emergency use authorization (EUA) of Novavax’ recombinant nanoparticle protein-based COVID-19 vaccine candidate with Matrix-M™ adjuvant. If authorized, the vaccine (known as NVX-CoV2373) will be manufactured by and commercialized by SII in South Africa under the brand name Covovax™.
COVAXIN™ (BBV152) Booster Dose Study Demonstrates Robust Immune Responses and Long-Term Safety Participants receiving a booster dose six months after second dose of COVAXIN™ saw significant increase (>10-fold across Alpha, Beta, Delta and Delta Plus variants) in neutralizing titers compared to baseline at six months Persistence of memory B and T cell immune responses at [….]